Skip to main content

Brittany Elliott

Research Associate, Senior
Medicine, Cardiology

Overview


My research focuses on advancing RNA-based therapeutics and understanding the role of non-coding RNAs (ncRNAs) in disease. I am particularly passionate about translational research—bridging the gap between bench and bedside—by targeting RNAs and engineering RNA-based therapies to treat inflammatory and rare diseases.

I am also deeply interested in deciphering the mechanisms by which small nucleolar RNAs (snoRNAs) influence disease states. My current projects include exploring how RPL13a snoRNAs regulate oxidative stress, and metabolic inflammation, with the ultimate goal of developing first-in-class antisense oligonucleotide (ASO) therapeutics. I am also working on predicting, capturing, and validating novel snoRNA interactions with transcripts that could inform on their unknown functions, expanding our understanding of snoRNA biology and their potential roles in health and disease. I further aspire to expand on detection of non-coding RNAs in clinical samples and linking them to disease progression, enabling more precise diagnostic and therapeutic approaches.

Through these activities, I strive to uncover how RNA-targeting therapies can address unmet clinical needs, particularly in diseases such as atherosclerosis, chronic inflammatory disease, and others. As a scientist, I am driven by the opportunity to connect fundamental discoveries with clinical applications, and I value fostering collaboration and mentoring the next generation of researchers in RNA biology and therapeutics.

Education:

PhD     University of South Carolina School of Medicine     2012

Training:

Postdoctoral Fellow     Medical University of South Carolina     2013-2015
Postdoctoral Fellow     Duke University                                          2016-2020

Current Appointments & Affiliations


Research Associate, Senior Medicine, Cardiology, Medicine

Recent Publications


m6A regulates breast cancer proliferation and migration through stage-dependent changes in Epithelial to Mesenchymal Transition gene expression.

Journal Article Front Oncol · 2023 While many factors have been implicated in breast cancer progression, effective treatments are still lacking. In recent years, it has become clear that posttranscriptional regulation plays a key role in the aberrant gene expression underlying malignancy an ... Full text Open Access Link to item Cite

Epitranscriptomic Addition of m5C to HIV-1 Transcripts Regulates Viral Gene Expression.

Journal Article Cell Host Microbe · August 14, 2019 How the covalent modification of mRNA ribonucleotides, termed epitranscriptomic modifications, alters mRNA function remains unclear. One issue has been the difficulty of quantifying these modifications. Using purified HIV-1 genomic RNA, we show that this R ... Full text Link to item Cite

Modification of messenger RNA by 2'-O-methylation regulates gene expression in vivo.

Journal Article Nat Commun · July 30, 2019 Epitranscriptomic modifications of mRNA are important regulators of gene expression. While internal 2'-O-methylation (Nm) has been discovered on mRNA, questions remain about its origin and function in cells and organisms. Here, we show that internal Nm mod ... Full text Open Access Link to item Cite
View All Publications

Recent Grants


IND-enabling studies for an RNA therapeutic to treat atherosclerosis

ResearchCo Investigator · Awarded by Department of Defense · 2024 - 2028

Targeting snoRNAs to Treat Atherosclerosis

ResearchSenior Scientist · Awarded by UH Harrington Discovery Institute · 2024 - 2026

Mechanisms by which Small Nucleolar RNAs Exacerbate Atherosclerosis

ResearchPostdoc Scholar · Awarded by National Institutes of Health · 2022 - 2026

View All Grants